Medicare AdvantagePrior AuthLow impact
Palsonify™ (paltusotine) (New)
Humana·Endocrinology·Medicare Advantage
Effective date
Jan 28, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has added prior authorization requirements for Palsonify (paltusotine), a new oral medication for acromegaly treatment. Claims will require approval showing inadequate response to surgery and trial/contraindication of octreotide or lanreotide.
Action Required
By January 28, 2026: Billing team must update prior authorization tracking system to include Palsonify (paltusotine) tablets for Medicare Advantage members. Providers treating acromegaly patients must obtain prior auth by documenting: 1) acromegaly diagnosis, 2) inadequate surgical response or surgery not an option, 3) trial failure or contraindication to octreotide/lanreotide. Visit www.humana.com/PAL for specific prior auth procedures.